Details of Disease

General Information of Disease (ID: DISYCNF1)

• Disease Name: Intestinal cancer
• Synonyms: malignant tumor of intestine; malignant intestinal tumor; bowel cancer; intestinal cancer; malignant intestine tumour; malignant neoplasm of the intestine; malignant tumor of the intestine; cancer of the intestine; malignant intestine tumor; malignant tumour of intestine; intestinal neoplasms, malignant; malignant tumour of the intestine; malignant intestinal neoplasm; intestinal tumors, malignant; malignant intestinal neoplasms; malignant neoplasm of intestine; malignant intestinal tumours; malignant intestine neoplasm; malignant intestinal tumour; intestine cancer; malignant intestinal tumors; cancer of intestine
• Disease Class: 2C0Z: Malignant intestine neoplasm
• Definition: A malignant neoplasm involving the intestine
• Disease Hierarchy:
  DISK0GUH: Intestinal neoplasm
  DISAT1Z9: Advanced cancer
  DIS3AOQ7: Aerodigestive tract cancer
  DISYCNF1: Intestinal cancer
• ICD Code:
  ICD-11: ICD-11: 2C0Z
  Expand ICD-10: C17,C18,C92
  Expand ICD-9: 152153205
• Disease Identifiers:
  MONDO ID: MONDO_0005814
  MESH ID: D007414
  UMLS CUI: C0346627
  MedGen ID: 87562
  SNOMED CT ID: 363508008

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Imatinib	DM7RJXL	Approved	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 13 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CDKN1B	TTLGFVW	Limited	Biomarker	[2]
NR1H4	TTS4UGC	Limited	Biomarker	[3]
NR5A2	TTAU3SY	Limited	Biomarker	[4]
PRKCA	TTFJ8Q1	Limited	Biomarker	[5]
PRKCD	TT7A1BO	Limited	Biomarker	[5]
XPA	TTGT87E	Limited	Biomarker	[6]
BAX	TTQ57WJ	Strong	Biomarker	[7]
CDKN1A	TT9GUW0	Strong	Altered Expression	[8]
DCLK1	TTOHTCY	Strong	Biomarker	[9]
KCNQ1	TT846HF	Strong	Biomarker	[10]
LGR5	TTTSGRH	Strong	Biomarker	[9]
MSI2	TTTXQF6	Strong	Biomarker	[11]
RSPO3	TT7HJTF	Strong	Biomarker	[12]

This Disease Is Related to 12 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
MUC2	OT3X4QVX	moderate	Biomarker	[13]
APC	OTKV0TIK	Strong	Genetic Variation	[14]
BOK	OTDQPDIX	Strong	Altered Expression	[7]
CSGALNACT1	OTBML9D9	Strong	Altered Expression	[15]
GGNBP2	OT7K9YZV	Strong	Biomarker	[16]
GPX2	OTXI2NTI	Strong	Biomarker	[17]
GSDME	OT1ZWY32	Strong	Biomarker	[18]
GUCA2A	OTUSF75G	Strong	Altered Expression	[19]
HLTF	OTRX2OSF	Strong	Biomarker	[20]
KRT15	OTS6WLF7	Strong	Biomarker	[21]
NHS	OTKE8QAT	Strong	Biomarker	[22]
SHMT1	OTIINA3J	Strong	Biomarker	[23]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
• [2] Somatic mutation of CDKN1B in small intestine neuroendocrine tumors.Nat Genet. 2013 Dec;45(12):1483-6. doi: 10.1038/ng.2821. Epub 2013 Nov 3.
• [3] Modulation of farnesoid X receptor results in post-translational modification of poly (ADP-ribose) polymerase 1 in the liver.Toxicol Appl Pharmacol. 2013 Jan 15;266(2):260-6. doi: 10.1016/j.taap.2012.11.012. Epub 2012 Nov 23.
• [4] LRH-1 drives hepatocellular carcinoma partially through induction of c-myc and cyclin E1, and suppression of p21.Cancer Manag Res. 2018 Aug 1;10:2389-2400. doi: 10.2147/CMAR.S162887. eCollection 2018.
• [5] Dietary copper affects azoxymethane-induced intestinal tumor formation and protein kinase C isozyme protein and mRNA expression in colon of rats.J Nutr. 2002 May;132(5):1018-25. doi: 10.1093/jn/132.5.1018.
• [6] Role of nucleotide excision repair deficiency in intestinal tumorigenesis in multiple intestinal neoplasia (Min) mice.Mutat Res. 2006 Dec 10;611(1-2):71-82. doi: 10.1016/j.mrgentox.2006.07.004. Epub 2006 Sep 8.
• [7] WNT signaling controls expression of pro-apoptotic BOK and BAX in intestinal cancer.Biochem Biophys Res Commun. 2011 Mar 4;406(1):1-6. doi: 10.1016/j.bbrc.2010.12.070. Epub 2010 Dec 22.
• [8] Paneth cell marker expression in intestinal villi and colon crypts characterizes dietary induced risk for mouse sporadic intestinal cancer.Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10272-7. doi: 10.1073/pnas.1017668108. Epub 2011 Jun 7.
• [9] Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine.J Exp Med. 2015 Nov 16;212(12):2057-75. doi: 10.1084/jem.20142288. Epub 2015 Nov 2.
• [10] The role of KCNQ1 in mouse and human gastrointestinal cancers.Oncogene. 2014 Jul 17;33(29):3861-8. doi: 10.1038/onc.2013.350. Epub 2013 Aug 26.
• [11] The Msi Family of RNA-Binding Proteins Function Redundantly as Intestinal Oncoproteins.Cell Rep. 2015 Dec 22;13(11):2440-2455. doi: 10.1016/j.celrep.2015.11.022. Epub 2015 Dec 8.
• [12] RSPO3 expands intestinal stem cell and niche compartments and drives tumorigenesis.Gut. 2017 Jun;66(6):1095-1105. doi: 10.1136/gutjnl-2016-311606. Epub 2016 Aug 10.
• [13] Short chain fatty acids and colon cancer.J Nutr. 2002 Dec;132(12):3804S-3808S. doi: 10.1093/jn/132.12.3804S.
• [14] Aldose Reductase Inhibitor, Fidarestat Prevents High-fat Diet-induced Intestinal Polyps in Apc(Min/+) Mice.Curr Cancer Drug Targets. 2018;18(9):905-911. doi: 10.2174/1568009617666170808105633.
• [15] Evaluation of SAT-1, SAT-2 and GalNAcT-1 mRNA in colon cancer by real-time PCR.Mol Cell Biochem. 2007 Apr;298(1-2):59-68. doi: 10.1007/s11010-006-9350-0. Epub 2006 Nov 21.
• [16] Differentiation-inducing factor-3 inhibits intestinal tumor growth invitro and invivo.J Pharmacol Sci. 2015 Apr;127(4):446-55. doi: 10.1016/j.jphs.2015.03.005. Epub 2015 Mar 24.
• [17] Glutathione peroxidases in different stages of carcinogenesis.Biochim Biophys Acta. 2009 Nov;1790(11):1555-68. doi: 10.1016/j.bbagen.2009.03.006. Epub 2009 Mar 13.
• [18] Determination of the Potential Tumor-Suppressive Effects of Gsdme in a Chemically Induced and in a Genetically Modified Intestinal Cancer Mouse Model.Cancers (Basel). 2019 Aug 20;11(8):1214. doi: 10.3390/cancers11081214.
• [19] Expression of guanylin is downregulated in mouse and human intestinal adenomas.Biochem Biophys Res Commun. 2000 Jun 24;273(1):225-30. doi: 10.1006/bbrc.2000.2917.
• [20] Loss of HLTF function promotes intestinal carcinogenesis.Mol Cancer. 2012 Mar 27;11:18. doi: 10.1186/1476-4598-11-18.
• [21] Mouse Intestinal Krt15+ Crypt Cells Are Radio-Resistant and Tumor Initiating.Stem Cell Reports. 2018 Jun 5;10(6):1947-1958. doi: 10.1016/j.stemcr.2018.04.022. Epub 2018 May 24.
• [22] Variation in post-colonoscopy colorectal cancer across colonoscopy providers in English National Health Service: population based cohort study.BMJ. 2019 Nov 13;367:l6090. doi: 10.1136/bmj.l6090.
• [23] SHMT1 inhibits the metastasis of HCC by repressing NOX1-mediated ROS production.J Exp Clin Cancer Res. 2019 Feb 12;38(1):70. doi: 10.1186/s13046-019-1067-5.